Braveheart Bio, Inc.: 5%+ holders

As of November 10, 2026, 5 holders' latest Schedule 13D or 13G filings report owning 5% or more of Braveheart Bio, Inc. The largest reported stake is Orbimed Advisors LLC's, at 13.5%. 6 filings are on record since August 14, 2026 (Schedule 13D/A, September 10, 2026).

Jiangsu Hengrui Pharmaceuticals Co., Ltd. also filed stake reports on 1 other company ↓

Sell to companies like Braveheart Bio, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Your website Find my buyers

Opens in a new tab. No signup.

Key facts

• Filing 2026-11-09 · Reporting person: Jiangsu Hengrui Pharmaceuticals Co., Ltd. · Sole voting: 7,420,091 · Shared voting: 0 · Sole dispositive: 7,420,091 · Shared dispositive: 0 · SCHEDULE 13G, 2026-11-09
• Filing 2026-11-05 · Reporting person: Fmr LLC · Sole voting: 7,374,365 · Shared voting: 0 · Sole dispositive: 7,374,365 · Shared dispositive: 0 · SCHEDULE 13G, 2026-11-05
• Filing 2026-09-10 · Reporting person: Orbimed Advisors LLC · Sole voting: 0 · Shared voting: 12,175,159 · Sole dispositive: 0 · Shared dispositive: 12,175,159 · SCHEDULE 13D/A, 2026-09-10
• Filed 2026-08-18 · Holder: Orbimed Advisors LLC · Percent: 17.2% · SCHEDULE 13D
• Filing 2026-08-14 · Reporting person: AH Bio Fund IV, L.P. · Sole voting: 10,232,420 · Shared voting: 0 · Sole dispositive: 10,232,420 · Shared dispositive: 0 · SCHEDULE 13D, 2026-08-14

Braveheart Bio, Inc. has 6 Schedule 13D or 13G filings on record since 2026-08-14. 5 holders' latest filing reports 5% or more of common stock, par value $0.0001 per share. Each figure below is the holder's own, as filed, with the filing linked.

Holders

Swipe the table sideways to see every column.

Holding shares or following this stake? See who's behind Braveheart Bio, Inc. and the warning signs.

See Braveheart Bio, Inc.'s free Snapshot Watch Braveheart Bio, Inc.: email me the next time it files something

Free to see. No signup.

Keep reading

More on Braveheart Bio, Inc. and the records around it.

Braveheart Bio, Inc. elsewhere on the record

• IPO filing Aug 2026
• Who owns it

Companies that share a holder

• Jiangsu Hengrui Pharmaceuticals Co., Ltd. also filed stake reports on 1 other company: Kailera Therapeutics, Inc. (Aug 2026)
• Frazier Life Sciences Public Fund, L.P. also filed stake reports on 25 other companies: PHATHOM PHARMACEUTICALS, INC. (Nov 2026), Q32 Bio Inc. (Oct 2026), ACLARIS THERAPEUTICS, INC. (Sep 2026)
• ORBIMED ADVISORS LLC also filed stake reports on 38 other companies: Aspen Neuroscience, Inc. (Nov 2026), ArriVent BioPharma, Inc. (Oct 2026), ADARx Pharmaceuticals, Inc. (Oct 2026)

Want the whole picture on Braveheart Bio, Inc.?

Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News

A Full Report on Braveheart Bio, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Braveheart Bio, Inc. covers

1. The Short Answer

2. Which Company This Is

3. What They Do, And How The Money Works

4. Who Runs It, And How To Reach Them

5. The Money: Funding, Valuation, Runway

6. Who Pays Them, And Who They Are Up Against

7. Warning Bells

8. Sources

   9 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

Order Full ReportSee a sample report

A real finished report, first screen. Opens in a new tab.

Voting and dispositive power, as filed

Swipe the table sideways to see every column.

The latest filing identifies Braveheart Bio, Inc. by CUSIP 10567X101 and gives its principal executive office as One Letterman Drive, Building A, Suite A, San Francisco, CA 94129 (SCHEDULE 13G, 2026-11-09).

What the percentages are based on

8.2% This percentage is calculated based on 90,038,969 shares of Common Stock outstanding, as reported by the Issuer in its quarterly report on Form 10-Q filed with the Securities and Exchange Commission on September 8, 2026.Jiangsu Hengrui Pharmaceuticals Co., Ltd., SCHEDULE 13G, 2026-11-09

Source of funds (Item 3)

Not applicable.Orbimed Advisors LLC, SCHEDULE 13D/A, 2026-09-10

Prior to the Issuer's initial public offering (the "IPO"), AH Bio IV, for itself and as nominee for AH Bio IV-B, AH Annual 2022, AH Annual 2022-B, AH Annual 2022-QC and CLF III, purchased 40,000,000 shares of the Issuer's Series A Preferred Stock for an aggregate purchase price of $40 million. In connection with the closing of the IPO, on August 7, 2026, the Series A Preferred Stock automatically converted into shares of common stock on a 4.38-for-1 basis, resulting in the issuance to AH Bio IV of an aggregate of 9,132,420 shares of common stock for no additional consideration.AH Bio Fund IV, L.P., SCHEDULE 13D, 2026-08-14

Purpose of Transaction (Item 4)

AH Bio Fund IV, L.P.

The Reporting Persons purchased the aforementioned securities for investment purposes with the aim of increasing the value of their investments and the Issuer. Subject to applicable legal requirements, one or more of the Reporting Persons may purchase additional securities of the Issuer from time to time in open market or private transactions, depending on its evaluation of the Issuer's business, prospects and financial condition, the market for the Issuer's securities, other developments concerning the Issuer, the reaction of the Issuer to the Reporting Persons' ownership of the Issuer's securities, other opportunities available to the Reporting Persons, and general economic, money market and stock market conditions. In addition, depending upon the factors referred to above (and subject to the Lock-Up Agreement described below), the Reporting Persons may dispose of all or a portion of their securities of the Issuer at any time (including by distribution to their respective members or limited partners, or by means of programs adopted pursuant to Rule 10b5-1 under the Act). Subject to applicable legal and contractual requirements, each of the Reporting Persons reserves the right to increase or decrease its holdings on such terms and at such times as each may decide. Except as set forth in this Item 4 and Item 6 below, none of the Reporting Persons has a present plan or proposal that relates to or would result in any of the actions specified in clauses (a) through (j) of …The first part of Item 4 of the SCHEDULE 13D filed 2026-08-14; the filing has the rest

Orbimed Advisors LLC

The Reporting Persons from time to time intend to review their investment in the Issuer on the basis of various factors, including the Issuer's business, financial condition, results of operations and prospects, general economic and industry conditions, the securities markets in general and those for the Issuer's Shares in particular, as well as other developments and other investment opportunities. Based upon such review, the Reporting Persons will take such actions in the future as the Reporting Persons may deem appropriate in light of the circumstances existing from time to time. If the Reporting Persons believe that further investment in the Issuer is attractive, whether because of the market price of Shares or otherwise, they may acquire Shares or other securities of the Issuer either in the open market or in privately negotiated transactions. Similarly, depending on market and other factors, the Reporting Persons may determine to dispose of some or all of the Shares currently owned by the Reporting Persons or otherwise acquired by the Reporting Persons either in the open market or in privately negotiated transactions. Except as set forth in this Schedule 13D, the Reporting Persons have not formulated any plans or proposals which relate to or would result in: (a) the acquisition by any person of additional securities of the Issuer or the disposition of securities of the Issuer, (b) an extraordinary corporate transaction, such as a merger, reorganization or liquidation, …The first part of Item 4 of the SCHEDULE 13D/A filed 2026-09-10; the filing has the rest

Timeline

Swipe the table sideways to see every column.

Questions about who owns Braveheart Bio, Inc.

Who owns Braveheart Bio, Inc.?

On this page, 5 holders' latest ownership filings report 5% or more of Braveheart Bio, Inc.: Orbimed Advisors LLC (13.5%, Schedule 13D/A, filed 2026-09-10), AH Bio Fund IV, L.P. (11.4%, Schedule 13D, filed 2026-08-14), Fmr LLC (8.2%, Schedule 13G, filed 2026-11-05), Jiangsu Hengrui Pharmaceuticals Co., Ltd. (8.2%, Schedule 13G, filed 2026-11-09) and Frazier Life Sciences Public Fund, L.P. (5.5%, Schedule 13G, filed 2026-08-14).

Who are the largest shareholders of Braveheart Bio, Inc.?

By the share each holder's latest filing reports, the largest holders of Braveheart Bio, Inc. on this page are Orbimed Advisors LLC (13.5%), AH Bio Fund IV, L.P. (11.4%) and Fmr LLC (8.2%).

When did Orbimed Advisors LLC buy into Braveheart Bio, Inc.?

The filings give report dates, not purchase dates. The earliest filing from Orbimed Advisors LLC on this page is the Schedule 13D, filed 2026-08-18, reporting 17.2%; its latest, Schedule 13D/A filed 2026-09-10, reports 13.5%.

Is this an audit or a full list?

Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 6 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.

Also on the record for Braveheart Bio, Inc.

Swipe the table sideways to see every column.

Tools for this story

Each opens in a new tab, filled in for Braveheart Bio, Inc.. With no account yet, you sign up free and land on the result.

• Get an alert when Braveheart Bio, Inc. is mentioned again
• Find former Braveheart Bio, Inc. employees to interview
• Verify a claim or statistic

Where this comes from

Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.

Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.

All recent stakesThat week's stakes